Latest Clinical & Research News
Brigham and Women’s Hospital investigators helped lead a multicenter, randomized, double-blind, sham-controlled trial of unilateral MRgFUS thalamotomy performed with the Exablate 4000 system (InSightec).
Read More...
In this clinical trial, investigators at Brigham and Women’s Hospital found that although pemafibrate therapy was associated with reduced plasma triglyceride levels and certain other lipids, it did not reduce the risk of cardiovascular events.
Read More...
Researchers in the Division of Endocrinology, Diabetes and Hypertension at Brigham and Women’s Hospital found thyroid-stimulating immunoglobulin bioassay (TSI) and thyrotropin-binding inhibitory immunoglobulin assay (TBII) performed similarly for discriminating Graves’ disease from other causes of thyrotoxicosis.
Read More...
Chondrocytes are quite fragile; even minor mechanical insults can result in substantial cell death and graft compromise. A Brigham study determined the optimal technique for harvesting the plugs and found both methods lead to significant mechanical injury at the edge of the explants compared with scalpel incision.
Read More...
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has been shown to improve clinical outcomes and prognosis in patients with peritoneal metastasis. However, it is associated with a significant complication rate and a long postsurgical recovery in the hospital.
Read More
The American Society of Colon and Rectal Surgeons and the Society of American Gastrointestinal and Endoscopic Surgeons published revised joint guidelines for developing enhanced recovery protocols for elective colon and rectal resection. Jennifer L. Irani, MD, at Brigham and Women’s Hospital, served as co–first author.
Read More...
Brigham and Women’s Hospital team has developed an automated two-way text messaging program designed to encourage self-monitoring of blood glucose in women with gestational diabetes mellitus.
Read More...
Researchers at Brigham and Women’s Hospital present additional evidence that both subjective and objective measures are of value in assessing functional status in patients with knee osteoarthritis.
Read More...
Marc S. Sabatine, MD, MPH, Michelle L. O’Donoghue, MD, MPH, and colleagues completed the phase 2 dose-finding OCEAN(a)-DOSE trial of olpasiran. They report that olpasiran was associated with dose-dependent reductions in lipoprotein(a), with decreases of more than 95% when administered every 12 weeks.
Read More...
With about 12,000 to 13,000 cases diagnosed in the United States each year, sarcomas are among medicine’s rarest cancers. Since many oncologists may only see one or two cases during their career, patients often struggle to find experienced providers. Read More